濟川藥業(600566.SH):全資子公司2款藥品退出河北省醫保目錄
格隆匯7月6日丨濟川藥業(600566.SH)公佈,根據河北省醫療保障局、河北省人力資源社會保障廳印發的關於調整《河北省基本醫療保險、工傷保險和生育保險藥品目錄(2020年版)》的通知,公司的全資子公司濟川藥業集團有限公司主要品種蒲地藍消炎口服液及蛋白琥珀酸鐵口服溶液於2021年6月30日從《河北省基本醫療保險、工傷保險和生育保險藥品目錄(2020年版)》退出,為保障參保人員用藥連續性,對調出藥品設置半年過渡期,過渡期截至2021年12月31日,過渡期內按原政策規定報銷。
2020年,蒲地藍消炎口服液在河北省的銷售金額約1.1億元,蛋白琥珀酸鐵口服溶液在河北省的銷售金額約5000萬元。藥品的具體銷售規模除受到醫保支付政策的影響外,還會受到產品療效、品牌影響力和用户的認可度等因素影響。公司藥品此次退出河北省醫保對公司經營業績的影響暫無法估計,短期不會對公司的業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.